Molecular therapy for triple-negative breast tumors: MiR-29b increases the levels of cell cycle inhibitor, p27, inhibits pro-survival pathways mediated by c-Myc, and inhibits the progression of triple-negative breast cancer via up-regulation of its target gene, 1/January/2017, 11.11 pm
Introduction: What they say A study from the Department of Cell and Tissue Biology, University of California, San Francisco (UCSF), San Francisco, California, USA shows that “PIM1 kinase inhibition as a targeted therapy against triple-negative breast tumors with elevated MYC expression” Another study, carried out in parallel, from the Breast Cancer Now Research Unit, Division […]
Molecular therapy for Bone disorders: SCYL1-BP1 inhibits the expression of Tgif2 and suppresses osteoporosis and bone metastasis via up-regulation of its target gene, 1/January/2017, 11.00 pm
Introduction: What they say: A study from the Department of Pharmacology, The University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA has reported that “miR-34a blocks osteoporosis and bone metastasis by inhibiting osteoclastogenesis and Tgif2.” This study was published in the June 25, 2014 Nature [I.F >42] by Prof. Wan Y, Krzeszinski and others from the Department of Pharmacology, The University of Texas Southwestern Medical Center, Dallas, […]
Natural product-derived therapy for tuberculosis: Gingerol, one of the main components of Ginger, increases the expression of MKP-1, inhibits TLR2 signalling, secretion of Chemokine CXCL5, and recruitment of polymorphonuclear leukocytes (PMNs), decreases destructive pulmonary inflammation, promotes M. tuberculosis clearance and inhibits pulmonary tuberculosis via up-regulation of its target gene, 1/January/2017, 10.57 pm
Introduction: What they say: A study from the Max Plank Institute for Infection Biology, Berlin, Germany shows that “CXCL5-secreting pulmonary epithelial cells drive destructive neutrophilic inflammation in tuberculosis.” This study was published in the 10 February 2014 issue of the“Journal of Clinical Investigation” [One of the best research journals in clinical medicine with an impact factor […]
Small molecule-based PD-1 pathway blockade for Human cancer therapy: ARIH2 inhibits the expression of co-inhibitory receptor PD-1 on Antigen- Specific T-cells, increases the production of cytokines by tumor-infiltrating lymphocytes (TIL), and draining lymph nodes and augments anti-tumor activity via down-regulation of its target gene, 1/January/2017, 10.02 pm
Introduction:What they say: A recent study from Division of Infectious Diseases, School of Medicine, Johns Hopkins University, Baltimore, MD 21218, United States shows that “TGF-β1-Mediated Smad3 Enhances PD-1 Expression on Antigen-Specific T Cells in Cancer.” This study was published in the 28 September 2016 issue of Cancer Discovery (one of the best journals in Cancer […]
Cardiac rejuvenation therapy: 17-β Estradiol (17-βE2) suppresses tumor suppressor INK4a/p16 expression, and inhibits dilated cardiomyopathy and heart failure via up regulation of its target gene, 1/January/2017, 12.32 pm
Introduction: What they say A recent study from the Stem Cell Aging Group, Centro Nacional de Investigaciones Cardiovasculares, E-28029 Madrid, Spain shows that “Bmi1 limits dilated cardiomyopathy and heart failure by inhibiting cardiac senescence.” This study was published in the online journal 9 March 2015 issue of Nature Communications by Prof Gonzalez, Gonzalez-Valdes and others. […]
Therapeutic insights into “awakening the sleeping/cancer-protecting angels” in mutant p53-expressing human tumors: Panax notoginseng saponins, isolated from Panax notoginseng (Burk), increases the expression of tumor suppressor p53 homologue TA-p73/p63, PTEN, TPM1, TIMP3, BTG2, PDCD4, SPRY1/2 and CCM1/KRIT1 and induces regression of p53-mutated human tumors via down regulation of its target gene, 1/January/2017, 11.23 am
From Significance of the study to Public health relevance: Given that: (1) Cancer suppressor p53 is mutated in more than 50% of human cancers of different tissue origin; (2) p53 pathway is altered in about 80% of tumors.; (3) our understanding is incomplete in terms of molecular targets and the oncogenic/malignant pathways involved in mutant […]
